Adar Poonawalla said if the vaccine trials go fine and the results are favourable, Serum Institute of India will be manufacturing this Covid-19 vaccine as a partner with Oxford University.
Serum Institute of India CEO Adar Poonawalla.
A day after the Lancet published the first human trial data of the Covid-19 vaccine that is being developed by the Oxford University, Serum Institute of India CEO Adar Poonawalla said 50 per cent of the vaccines that will be manufactured by his firm will be supplied to India and the rest to other countries. Poonawalla said the vaccine will mostly be purchased by governments, and people will receive them free of cost through immunisation programmes.
Serum Institute of India is one of the world's biggest vaccine manufacturers.
Speaking in an exclusive interview to India Today TV, Adar Poonawalla said if the vaccine trials go fine and the results are favourable, Serum Institute of India will be manufacturing this vaccine as a partner with Oxford University. He said the firm is also seeking regulatory clearances to conduct Phase 3 human trials of the Oxford University vaccine in India so that the vaccine can be manufactured at mass scale if the results are favourable.
"We have said that we want to give half of our (vaccine) production to India and the other half to other countries on a pro-rata basis every month. The government has been supportive. We need to understand that this is a global crisis and people across the world need to be protected. It's important that we equally immunise the entire world," Poonawalla said.
He said if the trials and results go as planned, Serum Institute of India would be able to produce a few million doses of the vaccine by November-December, and around 300-400 million doses by the first quarter of 2021 for mass usage.
Asked who would get the vaccine in the first batch, Poonawalla said they have left it to the government to decide on who requires the vaccine the most.
"The ethical way of distributing the vaccine is that the elderly and the immuno compromised (who are most vulnerable) get the vaccine first, along with frontline healthcare workers. The healthy adults can get the vaccine later on," he said, adding that this would be an ethical way of distributing the vaccine.
Speaking about the price component of this vaccine (if it materialises and hits the market), Adar Poonawalla said it is a bit early to comment on how much each dose of the vaccine will cost.
"Of course it will be given out at a very affordable price. Today, a Covid-19 test incurs Rs 2,500. There are drugs like Remdesiver that are costing tens and thousands of rupees. We are planning to put the price at around Rs 1,000 or less than that per dose. I don't think any individual will have to pay for it because the vaccines will mostly be bought by governments and then distributed free through the immunisation programmes," Poonawalla said.
He said, for African countries, his firm has committed to provide the vaccine at $2-3 per dose.
"It will in line with our philosophy of giving things at a very affordable price. We don't want to make a profit at all in the pandemic state. Once the pandemic is over, we may look at a more commercial price and the vaccine could be available in the private market like other drugs. But during the pandemic period, we have committed not to charge a very high price," Poonawalla said.
"I don't see any citizen having to pay for this vaccine... or at least they should not. It (coronavirus pandemic) is a national security issue and the government must put in its efforts, and they are doing it," he said.
Source - IndiaToday
Department of Biotechnology announces the scientific completion of India's first qHPV vaccine ‘CERVAVAC’
SII CEO Adar Poonawalla & Director Prakash Kumar Singh call on Hon'ble President of India Smt. Droupadi Murmu
Adar Poonawalla, CEO, Serum Institute of India, receives the award for the Outstanding Business Leader of the Year
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines
Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia
Serum Institute Of India sends out Covishield vaccine - Consignment of Covishield Vaccine arrived in Delhi, Chennai, Kolkata, Guwahati, Shillong, Ahmedabad, Hydrabad, Vijayawada, Bhubaneswar, Patna, Bengaluru, Lucknow, Chandigarh
Serum Institute of India launches India’s first fully indigenously developed pneumococcal vaccine, 'PNEUMOSIL'
Oxford COVID-19 vaccine: Serum Institute likely to submit final Covishield trial data within 10 days
SII’s Adar Poonawalla on Covid vaccine, pricing and rollout at Hindustan Times Leadership Summit 2020
COVISHIELD Completes Enrolment of Phase III clinical trials under partnership of ICMR and Serum Institute of India
Government Secures Vaccine Supplies For Half Of The Indian Population From Serum Institute And Novavax
IAVI, Merck, and Serum Institute of India Join Forces to Develop Monoclonal Antibodies for COVID-19 and Ensure Prompt and Equitable Global Access
Serum Institute Of India Takes A Multipronged Approach In Quest To Produce World’s First Covid-19 Vaccines
Serum Institute of India to produce up to an additional 100 million covid 19 vaccine doses for india and low and midle income countries in 2021
Adar Poonawalla CEO of Serum Institute of India, the world’s largest vaccine manufacturer, explains the timing, challenges & cost of vaccinating the world against COVID-19
Serum Institute looking for a $1 billion shot to fight covid, talks on with Blackstone, KKR and others
Serum Institute of India Says Covid Vaccine Likely to Be Ready by End of 2020, Final Pricing in 2 Months
Serum institute of india to produce up to 100 million covid-19 vaccine doses for india and low-and middle-income countries as early as 2021
50% of our Covid vaccines will be for India, people won't have to buy them, govts will pay: Adar Poonawalla
AstraZeneca vaccine's success in early human trials, Will Begin AstraZeneca Vaccine Trial in India After Applying for Licence Next Week, Says Serum Institute
Serum Institute of India CEO: ‘We plan to make millions of doses of Covid vaccine over three months’:’
New supply agreement between UNICEF and Serum Institute of India makes pneumococcal conjugate vaccine available at US$2.00 per dose, a 43 % reduction from the Gavi price at the start of the Advance Market Commitment
Serum Institute confident of manufacturing Covid vaccine’s 100 million doses if trials establish efficacy
Serum Institute’s Journey To Success | ET NOW Covid-19 vaccine possible by Q2 of 2022: Adar Poonawalla
Adar Poonawalla discusses Serum Institute's progress in the global battle against COVID-19 with Shereen Bhan, CNBC-TV18
Adar Poonawalla talks with Aabha Bakaya about the success story of Serum Institute of India. Tune in to know all about the journey of the company.
Bill Gates confers Indian Council of Medical Research "Lifetime Achievement Medal" on Dr. Cyrus Poonawalla
Dr. Cyrus Poonawalla conferred with 'Lifetime Achievement Award’ by the Asian Business Leadership Forum
Dr. Cyrus Poonawalla conferred with the prestigious honorary degree by the University of Oxford, U.K.